- Home
- RMAX vs DMAC Comparison
RMAX vs DMAC Comparison
Compare RMAX & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMAX
- DMAC
- Stock Information
- Founded
- RMAX 1973
- DMAC 2000
- Country
- RMAX United States
- DMAC United States
- Employees
- RMAX N/A
- DMAC N/A
- Industry
- RMAX Real Estate
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- RMAX Finance
- DMAC Health Care
- Exchange
- RMAX Nasdaq
- DMAC Nasdaq
- Market Cap
- RMAX 200.2M
- DMAC 224.6M
- IPO Year
- RMAX 2013
- DMAC N/A
- Fundamental
- Price
- RMAX $10.39
- DMAC $6.21
- Analyst Decision
- RMAX Hold
- DMAC Strong Buy
- Analyst Count
- RMAX 4
- DMAC 3
- Target Price
- RMAX $9.17
- DMAC $7.00
- AVG Volume (30 Days)
- RMAX 146.4K
- DMAC 93.1K
- Earning Date
- RMAX 02-20-2025
- DMAC 03-18-2025
- Dividend Yield
- RMAX N/A
- DMAC N/A
- EPS Growth
- RMAX N/A
- DMAC N/A
- EPS
- RMAX N/A
- DMAC N/A
- Revenue
- RMAX $311,818,000.00
- DMAC N/A
- Revenue This Year
- RMAX N/A
- DMAC N/A
- Revenue Next Year
- RMAX $0.81
- DMAC N/A
- P/E Ratio
- RMAX N/A
- DMAC N/A
- Revenue Growth
- RMAX N/A
- DMAC N/A
- 52 Week Low
- RMAX $6.94
- DMAC $2.14
- 52 Week High
- RMAX $14.31
- DMAC $6.41
- Technical
- Relative Strength Index (RSI)
- RMAX 47.03
- DMAC 64.37
- Support Level
- RMAX $9.86
- DMAC $5.65
- Resistance Level
- RMAX $10.23
- DMAC $5.85
- Average True Range (ATR)
- RMAX 0.41
- DMAC 0.43
- MACD
- RMAX 0.10
- DMAC 0.07
- Stochastic Oscillator
- RMAX 75.74
- DMAC 97.86
About RMAX RE/MAX Holdings Inc.
RE/MAX Holdings Inc operates as a franchisor of real estate brokerage services. It recruits and retains agents and sells franchises. The company's operating segments include Real Estate, Mortgage, Marketing Funds, and Others. It generates maximum revenue from the Real Estate segment.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.